[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617501":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"ImmunoRegister gUG","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Stefanie Howaldt, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+4940423265150","Howaldt@immunoregister.de",[18],{"facility":5,"status":19,"city":20,"state":7,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Hamburg","20251","Germany","DE",{"type":25,"coordinates":26},"Point",[27,28],9.99302,53.55073,{"lat":28,"lon":27},[31],{"name":10,"role":14,"phone":32,"phoneExt":7,"email":16},"+4930423265150",{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100617501","cedur---german-ibd-registry-100617501",false,"NCT07319442","CEDUR - German IBD Registry","Long-term Observation of IBD Patients, a Nationwide German IBD Registry \"CEDUR\"","CEDUR","Inclusion Criteria:\n\n* Crohn Disease Ulcerative Colitis Indterminate Colitis\n\nExclusion Criteria:\n\n* Other gastrointestinal disorders than above","ALL","18 Years",{"count":46,"type":47},10000,"ESTIMATED","10 Years","OBSERVATIONAL","The CEDUR registry systematically collects real-world data on inflammatory bowel disease (IBD) patients in Germany. The registry aims to assess quality of care, disease activity, treatment effectiveness, safety, and pharmacoeconomic aspects under routine clinical conditions.",[52,53,54],"Ulcerative Colitis (UC)","Indeterminate Colitis","Crohn Disease (CD)",[56,57,58,59,60,22,61,62,63,64,65,66],"IBD","Registry","Crohn's disease","Ulcerative Colitis","Real-world-data","Quality of care","pharmaeconomics","safety","long-term follow-up","patient journey","treatment algorithm","2025-12-21",{"date":69,"type":70},"2026-01-06","ACTUAL",{"date":72,"type":70},"2018-05-03",{"date":74,"type":47},"2036-05",{"name":5,"class":6},1]